{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"190.0","upperLimit":"274.0","value":"222.0"},{"groupId":"OG001","lowerLimit":"94","upperLimit":"224.0","value":"119.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"Kaplan-Meier estimates of time to first new flare and confidence intervals were determined. For patients with event, time to event = (date of event - date of first dose of study drug + 1).\n\nPatients met definition of new flare if they had:\n\n* Flare in joint, not a previously affected joint (at baseline or during study)\n* Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely.\n\nPatients did not meet criterion of having new gout flare if:\n\n· Increasing/renewed gout pain in an affected joint before flare has resolved completely.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.\n\nAfter completing the first extension study, patients were offered to enter the second extension study, whereby all patients were treated open-label \"on demand\" with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study. Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"72 weeks overall","title":"Time to First New Flare: Survival Analysis by Treatment (72 Weeks Overall)","type":"SECONDARY","unitOfMeasure":"days"}